J. H. Hoofnagle

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

B. Garra, S. Steinberg, J. Hoofnagle, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term therapy of chronic delta hepatitis with peginterferon alfa

Y. Rotman, C. Koh, T. Heller, 2014, Alimentary pharmacology & therapeutics.

Hepatitis C in African Americans: summary of a workshop.

J. Hoofnagle, C. Howell, L. Jeffers, 2000, Gastroenterology.

Statistical models for predicting a beneficial response to interferon‐α in patients with chronic hepatitis B

J. Hoofnagle, L. Comanor, J. Minor, 1998, Journal of viral hepatitis.

Ratio of Serum Aspartate to Alanine Aminotransferase in Chronic Hepatitis

J. H. Hoofnagle, B. Williams, 1988 .

Conditions associated with hepatocellular carcinoma.

J. Hoofnagle, M. Lisker‐Melman, P. Martín, 1989, The Medical clinics of North America.

Serologic markers of hepatitis B virus infection.

J. Hoofnagle, D. Schafer, J. H. Hoofnagle, 1986, Seminars in liver disease.

Liver injury is associated with mortality in sickle cell disease

M. Gladwin, J. Nichols, J. Hoofnagle, 2015, Alimentary pharmacology & therapeutics.

Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis.

J. Hoofnagle, G. Minuk, G. Dusheiko, 1984, Gastroenterology.

Selective immunoglobulin A deficiency associated with primary biliary cirrhosis in a family with liver disease.

J. H. Hoofnagle, D. F. Schafer, E. A. Jones, 1986, Gastroenterology.